Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 118Observational 59Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Neoplasms 37Carcinoma, Non-Small-Cell Lung 34Multiple Myeloma 32Recurrence 29Prostatic Neoplasms 28Melanoma 21Leukemia, Myeloid, Acute 21Breast Neoplasms 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Glioblastoma 15Pancreatic Neoplasms 14Sarcoma 13Neuroblastoma 13Lymphoma 13Glioma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia 10Ovarian Neoplasms 9Lung Neoplasms 9Colorectal Neoplasms 9Carcinoma, Hepatocellular 9Small Cell Lung Carcinoma 8Lymphoma, Large B-Cell, Diffuse 8Lambert-Eaton Myasthenic Syndrome 8Pheochromocytoma 7Neuroendocrine Tumors 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Gastrointestinal Stromal Tumors 7Carcinoma, Renal Cell 7

Interventions

selpercatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Thyroid Cancer, Papillary × Clear all
NCT03906331 2025-01-17

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Eli Lilly and Company

Approved for marketing
BreastEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡